• news.cision.com/
  • Episurf/
  • Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2021

Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2021

Report this content

In accordance with decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee.

In accordance with the above principles, the Nomination Committee consists of the following four members:

  • Dennis Stripe, Chairman of the Board of Episurf Medical AB
  • Leif Ryd, representing Niles Noblitt
  • Robert Charpentier, representing Carl Palmstierna
  • Max Mennfort, representing Pål Ryfors

The members of the Nomination Committee have been appointed based on the ownership structure as of August 31, 2020.

The Nomination Committee has appointed Robert Charpentier as its Chairman.

The shareholders having appointed members of the Nomination Committee together represent approximately 6 per cent of the voting rights for all shares in Episurf Medical.

Shareholders may contact the Committee with proposals regarding the work of the committee. Proposals shall be submitted in due time before the Annual General Meeting to ensure that the proposals can be considered. Proposals must be sent to the Chairman of the nomination committee, via ir@episurf.com.

For more information, please visit the company website: www.episurf.com.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.